A new study published in the peer-reviewed journal Scientific Reports has delivered a quiet but devastating blow to one of the most relied-upon tools in modern mainstream medicine: the PCR test. Conducted by researchers from the US Army Medical Research Institute of Infectious Diseases (USAMRIID), the paper reveals that PCR testing for Ebola virus produced wildly contradictory results when the same human blood samples were tested multiple times.
This is not a minor technical footnote. It strikes at the very heart of how they diagnose and respond to infectious disease outbreaks.
The military scientists took multiple aliquots from the same blood samples of Ebola patients and ran them through standard PCR protocols. What they found was alarming: results varied significantly between runs. Samples that tested positive in one test would come back negative or inconclusive in another. The cycle threshold (Ct) values, the key number that indicates how much viral material was supposedly present, fluctuated dramatically even though the samples came from the exact same blood draw.
This mirror concerns that were repeatedly raised during the COVID-19 pandemic. High cycle thresholds often picked up harmless fragments of genetic material rather than active, infectious virus. Yet public health authorities treated almost every positive PCR result as a confirmed case, driving fear, lockdowns, and policy responses. Now we see the same testing platform producing inconsistent results for Ebola, one of the most feared viruses on earth.
The implications are profound. If PCR testing for Ebola is this unreliable, how can we trust the case numbers, the severity assessments, or the urgent calls for new vaccines and emergency measures? The current outbreak in the Democratic Republic of Congo is already being used to justify rapid vaccine development contracts, including Moderna's new $50 million deal. Yet if the foundational diagnostic tool is flawed, the entire response risks being built on shaky ground.
The US military researchers were careful in their language, but their findings cannot be easily dismissed. These are not armchair critics or conspiracy theorists, they are scientists working inside one of the world's premier biodefense laboratories. Their data suggests that PCR for Ebola suffers from the same reproducibility problems that plagued COVID testing: sensitivity that is too high for practical use, combined with variability that makes consistent interpretation difficult.
This should force a serious reckoning. For years, PCR has been sold to the public as the gold standard; fast, accurate, and definitive. In reality, it is a powerful amplification tool that requires strict controls, proper cycle thresholds, and clinical context to be meaningful. Without those safeguards, it becomes prone to false positives, over-diagnosis, and the kind of panic-driven responses we saw during COVID.
As another Ebola outbreak unfolds, we are once again watching familiar institutions mobilise with familiar urgency. Contracts are being signed. Trials are being fast-tracked. Fear is being cultivated. Before the medical elites repeat the same mistakes, we should demand far greater transparency about the reliability of the tests being used to drive policy.
The US military's own researchers have now documented serious inconsistencies in Ebola PCR testing. That alone should make every sensible person pause before accepting the official narrative at face value.
https://jonfleetwood.substack.com/p/us-military-confirms-ebola-pcr-tests